Inform Diagnostics
Search
6655 N MacArthur Blvd , Irving TX 75039
• 866.588.3280
Pay My BillPagar Mi Cuenta
  • About Us
    • Our Services
      • For Clinicians
        • For Patients
          • For Payors
            • Careers
              • Contact Us
                • Call Today Call Today
                • Email Us
                • Our Map
                • Menu
                • About Us
                  • Management Team
                  • Laboratory Certifications
                  • Conferences
                  • Testimonials
                  • Scientific Publications
                  • News
                  • Locations
                • Our Services
                  • Breast Pathology
                  • Dermatopathology
                  • GI Pathology
                  • Hematopathology
                  • Urologic Pathology
                  • Genomic Testing
                  • Technology
                  • Research & Development Services
                • For Clinicians
                  • Clinician Login
                  • Testimonials
                  • Forms & Requisitions
                  • Pay a Bill
                  • Additional Resources For Your Practice
                • For Patients
                  • Educational Resources
                  • Pay a Bill
                  • Pagar Mi Cuenta
                • For Payors
                  • Why Network Providers Choose Inform Diagnostics
                • Careers
                  • Employment Listings
                  • Working Here
                  • Benefits
                • Contact Us
                Scientific Publications 2011 December Getting to the point: Somatic point mutations influence the clinical features and survival in myelodysplastic syndromes
                Dec 1, 2011

                Getting to the point: Somatic point mutations influence the clinical features and survival in myelodysplastic syndromes

                RUN1, TP53, and NRAS were strongly associated with severe thrombocytopenia and an increased proportion of bone marrow blasts.

                TP53, EZH2, ETV6, RUNX1, and ASXL1 mutations were identified in 137 of the 439 (31.2%) study patients.

                TP53, EZH2, ETV6, RUNX1, and ASXL1 had prognostic significance independent of other established risk factors, predicting poor overall survival.

                According to the National Institutes of Health, the frequency and incidence of myelodysplastic syndromes (MDS) is increasing in the US population and is influenced by factors such as advancing age, the use of cytotoxic and mutagenic therapies for cancer, and greater exposure to environmental toxins. MDS is a heterogeneous group of disorders with some patients having an insidious onset of the disease, while others experience dramatic presentations including marrow failure or acute myeloid leukemia. The treatment is determined by the prognostic risk as determined by prognostic scoring systems, such as the International Prognostic Scoring System (IPSS) which incorporates the clinical features, bone marrow and peripheral blood findings, and karyotypic abnormalities. Approximately half of all patients have a normal karyotype. Single gene mutations are not currently considered in prognostic scoring systems but may be important in further defining MDS clinical phenotypes, risk stratification, and appropriate therapies.

                Gene mutations reported to influence overall survival include: TP53, NRAS, RUNX1, TET2, and IDH1 and IDH2. Only TP53 gene mutations have been found to be associated with poor prognostic markers, such as a complex karyotype. Recent research reported by Bejar, et al. in the New England Journal of Medicine examined the influence that independent somatic point mutations may exert on the clinical phenotype and prognosis in a large group of patients with MDS.

                The researchers identified somatic mutations in 18 genes, including two genes (ETV6 and GNAS) that were not previously reported to be mutated in MDS patients. Several of the somatic mutations correlated with features of a specific clinical phenotype which included certain cytopenias, blast percentage, cytogenetic abnormalities, and overall survival. RUNX1, TP53, and NRAS were strongly associated with severe thrombocytopenia and an increased proportion of bone marrow blasts. Mutations in one or more of these genes, TP53, EZH2, ETV6, RUNX1, and ASXL1, were identified in 137 of the 439 (31.2%) study patients and had prognostic significance independent of other established risk factors, predicting poor overall survival.

                This study demonstrates that somatic point mutations are common in MDS, associated with specific clinical features, and predict poor overall survival, independent of other established risk factors. The findings support a role for identifying these specific mutations in explaining the heterogeneity of the myelodysplastic syndromes and improving the risk stratification of these patients for better therapeutic intervention.

                References

                Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., and Ebert, B. L. (2011). Clinical effect of point mutations in myelodysplastic syndromes. The New England Journal of Medicine, 364(26):2496-2506.

                Kaneko H, Misawa S, Horiike S, Nakai H, Kashima K. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood 1995;85:2189-93.

                Kita-Sasai Y, Horiike S, Misawa S, et al. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. Br J Haematol 2001;115:309-12.

                Categories

                • Hematology
                Previous Next

                Recent Posts

                • Therapeutic Drug Monitoring of Monoclonal Antibody in Inflammatory Bowel Diseases: Laboratory Evidence to Predict Patient Responses
                • Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells
                • Human Papillomavirus (HPV) Genotypes in Condylomas, Intraepithelial Neoplasia, and Invasive Carcinoma of the Penis Using Laser Capture Microdissection (LCM)-PCR: A Study of 191 Lesions in 43 Patients
                • Importance of Universal Mismatch Repair Protein Immunohistochemistry in Patients with Sebaceous Neoplasia as an Initial Screening Tool for Muir-Torre Syndrome
                • Identification of HRAS Mutations and Absence of GNAQ or GNA11 Mutations in Deep Penetrating Nevi
                • Distribution and characterization of subtypes of penile intraepithelial neoplasia and their association with invasive carcinomas: a pathological study of 139 lesions in 121 patients
                • Papillary squamous cell carcinoma, not otherwise specified (NOS) of the penis: clinicopathologic features, differential diagnosis, and outcome of 35 cases
                • Distinctive immunohistochemical profile of penile intraepithelial lesions: a study of 74 case

                Categories

                • Abstracts & Presentations (65)
                • Dermatology (40)
                • Gastroenterology (101)
                • Hematology (10)
                • Peer-Reviewed Publications (18)
                • Urology (12)

                Conferences

                See where Inform Diagnostics will be exhibiting next.

                Get News From Inform Diagnostics

                Join our email list!

                Inform Diagnostics
                Inform Diagnostics Inform Diagnostics 6655 N MacArthur Blvd, Irving, TX 75039 View Map [+] 866.588.3280 http://www.informdx.com/
                • Latest News
                • Careers
                • Privacy Practices
                • Link Policy